23 September 2022
The Federal Antimonopoly Service (FAS) of the Russian Federation has approved prices for the first antitumor generic with INN eribulin. This was reported by the FAS press service.
“The agreed marginal prices for Eribulin-Promomed produced by AO Biokhimik are 27% lower than the prices for the foreign-made reference drug. This will make it more affordable for Russian citizens,” the report says.
The approved price of one vial of the domestic drug is 17,476 rubles, while the marginal cost of a similar vial of the reference drug is 23,794 rubles, the Federal Antimonopoly Service stressed.
The FAS previously approved the price of Convacel COVID vaccine.
PrintNovaMedica to localize in Russia one of the most popular anti-migraine drugs in the world
21 March 2023
Merry Christmas and Happy New Year!
27 December 2022
15 December 2022
In April 2023 drugs worth of 54.3 billion rubles were produced in Russia
09 June 2023
In Russia, child mortality is declining, while life expectancy is growing
09 June 2023
How can biopharma strengthen its resilience?
08 June 2023
Sergey Glagolev: Foreign companies are interested in conducting clinical trials in Russia
08 June 2023